Evaluating the diagnostic accuracy of a ctDNA methylation classifier for incidental lung nodules: protocol for a prospective, observational, and multicenter clinical trial of 10,560 cases

Wenhua Liang, Dan Liu, Min Li, Wei Wang, Zheng Qin, Jian Zhang, Yong Zhang, Yang Hu, Hairong Bao, Yi Xiang, Bo Wang, Jing Wu, Jianyu Sun, Chengping Hu, Xianwei Ye, Xiangyan Zhang, Wei Xiao, Chunmei Yun, Dejun Sun, Wei Wang, Ning Chang, Yunhui Zhang, Jianping Zhao, Xin Zhang, Jinfu Xu, Di Wu, Xiaoju Liu, Yubiao Guo, Qichuan Zhang, Wei Zhang, Lan Yang, Zhanqing Li, Xiaoju Zhang, Baohui Han, Zhaohui Tong, Jianxing He, Jieming Qu, Jian-Bing Fan, Nanshan Zhong, Wenhua Liang, Dan Liu, Min Li, Wei Wang, Zheng Qin, Jian Zhang, Yong Zhang, Yang Hu, Hairong Bao, Yi Xiang, Bo Wang, Jing Wu, Jianyu Sun, Chengping Hu, Xianwei Ye, Xiangyan Zhang, Wei Xiao, Chunmei Yun, Dejun Sun, Wei Wang, Ning Chang, Yunhui Zhang, Jianping Zhao, Xin Zhang, Jinfu Xu, Di Wu, Xiaoju Liu, Yubiao Guo, Qichuan Zhang, Wei Zhang, Lan Yang, Zhanqing Li, Xiaoju Zhang, Baohui Han, Zhaohui Tong, Jianxing He, Jieming Qu, Jian-Bing Fan, Nanshan Zhong

Abstract

Background: Lung nodules are a diagnostic challenge. Current clinical management of lung nodule patients is inefficient and therefore causes patient misclassification, which increases healthcare expenses. However, a precise and robust lung nodule classifier to minimize discomfort for patients and healthcare costs is still lacking. The aim of the present protocol is to evaluate the effectiveness of using a liquid biopsy classifier to diagnose nodules compared to physician estimates and whether the classifier can reduce the number of unnecessary biopsies in benign cases.

Methods: A prospective cohort of 10,560 patients enrolled at 23 clinical centers in China with non-calcified pulmonary nodules, ranging from 0.5 to 3 cm in diameter, indicated by LDCT or CT will be included. After signed consent forms, the participants' pulmonary nodules will be assessed using three evaluation tools: (I) physician cancer probability estimates (II) validated lung nodule risk models, including Mayo Clinic and Veteran's Affairs models (III) ctDNA methylation classifier previously established. Each patient will undergo LDCT/CT follow-ups for 2 to 3 years and their information and one blood sample will be collected at baseline, 3, 6, 12, 24 and 36 months. The primary study outcomes will be the diagnostic accuracy of the methylation classifier in the cohort. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) will be used to compare the diagnostic value of each testing tool in differentiating benign and malignant pulmonary nodules.

Discussion: We are conducting an observational study to explore the accuracy of using a ctDNA methylation classifier for incidental lung nodules diagnosis.

Trial registration: Clinicaltrials.gov NCT03651986.

Keywords: Pulmonary nodule; liquid biopsy; lung cancer early diagnosis.

Conflict of interest statement

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/tlcr-20-701). WL serves as an unpaid editorial board member of Translational Lung Cancer Research from Apr 2018 to Apr 2021. The other authors have no conflicts of interest to declare.

2020 Translational Lung Cancer Research. All rights reserved.

Figures

Figure 1
Figure 1
Different areas of DNA methylation in malignant and benign pulmonary nodules.
Figure 2
Figure 2
Summary of research procedures.

References

    1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115-32. 10.3322/caac.21338
    1. Shankar A, Saini D, Dubey A, et al. Feasibility of lung cancer screening in developing countries: challenges, opportunities and way forward. Transl Lung Cancer Res 2019;8:S106-21. 10.21037/tlcr.2019.03.03
    1. Takashima S, Sone S, Li F, et al. Small solitary pulmonary nodules (< or =1 cm) detected at population-based CT screening for lung cancer: Reliable high-resolution CT features of benign lesions. AJR Am J Roentgenol 2003;180:955-64. 10.2214/ajr.180.4.1800955
    1. Ferrari A, Bertolaccini L, Solli P, et al. Digital chest tomosynthesis: the 2017 updated review of an emerging application. Ann Transl Med 2018;6:91. 10.21037/atm.2017.08.18
    1. Ettinger DS, Wood DE, Aisner DL, et al. Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2017;15:504-35. 10.6004/jnccn.2017.0050
    1. Wender R, Fontham ET, Barrera E, Jr, et al. American Cancer Society lung cancer screening guidelines. CA Cancer J Clin 2013;63:107-17. 10.3322/caac.21172
    1. Wu J, Zan X, Gao L, et al. A Machine Learning Method for Identifying Lung Cancer Based on Routine Blood Indices: Qualitative Feasibility Study. JMIR Med Inform 2019;7:e13476. 10.2196/13476
    1. Bai C, Choi CM, Chu CM, et al. Evaluation of Pulmonary Nodules: Clinical Practice Consensus Guidelines for Asia. Chest 2016;150:877-93. 10.1016/j.chest.2016.02.650
    1. Jones PA. Functions of DNA methylation: islands, start sites, gene bodies and beyond. Nat Rev Genet 2012;13:484-92. 10.1038/nrg3230
    1. Hollstein M, Sidransky D, Vogelstein B, et al. p53 mutations in human cancers. Science 1991;253:49-53. 10.1126/science.1905840
    1. Crowley E, Di Nicolantonio F, Loupakis F, et al. Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol 2013;10:472-84. 10.1038/nrclinonc.2013.110
    1. Diaz LA, Jr, Bardelli A. Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol 2014;32:579-86. 10.1200/JCO.2012.45.2011
    1. Cai X, Janku F, Zhan Q, et al. Accessing Genetic Information with Liquid Biopsies. Trends Genet 2015;31:564-75. 10.1016/j.tig.2015.06.001
    1. Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014;6:224ra24. 10.1126/scitranslmed.3007094
    1. Forshew T, Murtaza M, Parkinson C, et al. Noninvasive identification and monitoring of cancer mutations by targeted deep sequencing of plasma DNA. Sci Transl Med 2012;4:136ra68. 10.1126/scitranslmed.3003726
    1. Sun K, Jiang P, Chan KC, et al. Plasma DNA tissue mapping by genome-wide methylation sequencing for noninvasive prenatal, cancer, and transplantation assessments. Proc Natl Acad Sci U S A 2015;112:E5503-12. 10.1073/pnas.1508736112
    1. Guo S, Diep D, Plongthongkum N, et al. Identification of methylation haplotype blocks aids in deconvolution of heterogeneous tissue samples and tumor tissue-of-origin mapping from plasma DNA. Nat Genet 2017;49:635-42. 10.1038/ng.3805
    1. Liang W, Zhao Y, Huang W, et al. Non-invasive diagnosis of early-stage lung cancer using high-throughput targeted DNA methylation sequencing of circulating tumor DNA (ctDNA). Theranostics 2019;9:2056. 10.7150/thno.28119
    1. Chan AW, Tetzlaff JM, Altman DG, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013;158:200-7. 10.7326/0003-4819-158-3-201302050-00583

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다